- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
Patent holdings for IPC class C07D 295/10
Total number of patents in this class: 92
10-year publication summary
|
8
|
4
|
5
|
10
|
7
|
1
|
1
|
1
|
3
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Epics Therapeutics | 20 |
5 |
| Adeka Corporation | 1367 |
4 |
| Theravance Biopharma R&D IP, LLC | 453 |
4 |
| The Regents of the University of California | 20303 |
3 |
| Mitsui Chemicals, Inc. | 3230 |
3 |
| Duke University | 3125 |
3 |
| The University of North Carolina at Chapel Hill | 2067 |
3 |
| Janssen Pharmaceutica N.V. | 3358 |
2 |
| Bioprojet | 42 |
2 |
| DAC S.r.l. | 11 |
2 |
| Korea University Research and Business Foundation | 3080 |
2 |
| Kyungpook National University Industry-Academic Cooperation Foundation | 1176 |
2 |
| The United States Government AS represented by The Department of Veterans Affairs | 1248 |
2 |
| The University of Manchester | 454 |
2 |
| Genecode | 6 |
2 |
| Novartis AG | 10612 |
1 |
| F. Hoffmann-La Roche AG | 7937 |
1 |
| Hoffmann-La Roche Inc. | 3546 |
1 |
| AstraZeneca AB | 2857 |
1 |
| Boehringer Ingelheim International GmbH | 4636 |
1 |
| Other owners | 46 |